News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CSPC PHARMA (01093.HK) Dual-Target CAR-T Cell Injection Approved for Clinical Trials in China
CSPC PHARMA (01093.HK) announced that its first mRNA-LNP-based dual-target chimeric antigen receptor T-cell injection (SYS6063 injection) developed by the group has been approved b...
Reset
Send
The window will close in 5 seconds
CSPC PHARMA (01093.HK) Dual-Target CAR-T Cell Injection Approved for Clinical Trials in China
Close
Recommend
5
Positive
9
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CSPC PHARMA (01093.HK)  -0.320 (-4.227%)    Short selling $210.03M; Ratio 23.438%   announced that its first mRNA-LNP-based dual-target chimeric antigen receptor T-cell injection (SYS6063 injection) developed by the group has been approved by the National Medical Products Administration of China to conduct clinical trials in China.

The approved clinical indication is relapsed and refractory systemic lupus erythematosus. In addition, the product is expected to be used for the treatment of other B-cell/plasma cell-mediated autoimmune diseases, including myasthenia gravis, rheumatoid arthritis, and anti-neutrophil cytoplasmic antibody-associated vasculitis. It may also be expanded to hematologic malignancies such as relapsed/refractory multiple myeloma and B-cell lymphoma, demonstrating significant clinical development value. (sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-03 16:25.)

Related News CLSA: CSPC PHARMA (01093.HK) 1Q26 Beats; Reiterate "Conviction List Outperform" with TP HKD19

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.